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Peripheral killer cells do not differentiate between asthma 
patients with or without fixed airway obstruction 
 
Abstract 
Objective:  The three main types of killer cells – CD8+ T cells, NK cells and NKT 
cells – have been linked to asthma and chronic obstructive pulmonary disease 
(COPD). However, their role in a small subset of asthma patients displaying fixed 
airway obstruction (FAO), similar to that seen in COPD, has not been explored.  
The objective of the pr sent study was to investigate killer cell numbers, 
phenotype and function in peripheral blood from asthma patients with FAO, 
asthma patients without FAO, and healthy individuals.  Methods:  Peripheral 
CD8+ T cells (CD8+CD3+CD56-), NK cells (CD56+CD3-) and NKT-like cells 
(CD56+CD3+) of 14 asthma patients with FAO (post-bronchodilator FEV/FVC 
<0.7, despite clinician-optimised treatment), 7 asthma patients without FAO 
(post-bronchodilator FEV/FVC ≥0.7), and 9 healthy individuals were studied. 
Results:  No significant differences were seen between the number, receptor 
expression, MAPK signalling molecule expression, cytotoxic mediator expression, 
and functional cytotoxicity of peripheral killer cells from asthma patients with 
FAO, asthma patients without FAO and healthy individuals.  Conclusions:  
Peripheral killer cell numbers or functions do not differentiate between asthma 
patients with or without fixed airway obstruction. 
Keywords 
CD8+ T cells; fixed airflow obstruction; natural killer cells; natural killer T cells; 
protein lysate microarray; asthma.  
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Introduction 
Asthma is a chronic inflammatory disease of the airways, with over 200 million 
individuals affected worldwide [1].  It is characterised by airway hyper-
responsiveness and remodelling resulting in coughing, breathlessness and chest 
tightness. Asthma encompasses a variety of clinical phenotypes ranging from 
what was classically defined as extrinsic allergic (IgE-mediated) asthma to 
intrinsic non-allergic asthma [2].  Recent genomic, transcriptomic and proteomic 
investigations of asthma, in combination with clinico-pathological parameters, 
have led to the realisation that clinically-diagnosed asthma encompasses a 
diverse and complex set of conditions referred to as ‘endotypes’ [3-5].  These 
range from classical allergic asthma (Th2-driven, IgE-mediated , eosinophilic), 
through neutrophilic asthma associated with the activation of innate immunity, 
to asthma involving little inflammation , but extensive airway remodelling [3-5]. 
It has also become apparent that the traditional distinction between asthma and 
chronic obstructive pulmonary disease (COPD) is not always applicable, with 
some patients having features of both of these conditions [6-8]. 
The majority of people with asthma display airflow obstruction that is 
episodic and returns to normal either spontaneously or following appropriate 
treatment. However, a minority of people with asthma display airflow 
obstruction that does not respond to treatment, i.e. can be described as ‘fixed’ 
([9-22], reviewed in [23]). This fixed airflow obstruction (FAO) is a feature more 
commonly associated with COPD [24]. It is not known why some asthma patients 
develop FAO. It may be a consequence of more severe asthma, duration of 
asthma, or it may represent a separate disease entirely.  
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In recent years, interest and investigations into the potential role of killer 
cells in asthma and COPD have steadily increased. CD8 T cells, NK cells and NKT 
cells are the three main killer cells types; their effector functions include cellular 
cytotoxicity and immunoregulation [25-36].  Killer cells are thought also to 
contribute to COPD [37-39].  We have previously shown that, in COPD, the 
numbers of peripheral blood NK and NK-T cells were reduced and that their 
cytotoxic function was defective compared to healthy smokers and never-
smokers [40]. 
Far fewer studies have looked at the role that killer cells play in asthma 
with FAO. Immunohistochemistry has shown the degree of FAO to be 
significantly correlated to the number of CD8 T cells in bronchial biopsies [19]. 
In this study, we have investigated the number and function of peripheral human 
killer cells in asthma with or without FAO to see if these differ, and to determine 
whether asthma with FAO is more similar to COPD or asthma without FAO in this 
respect. 
 
Material and methods 
Study population and procedures 
The Nottingham Local Research Ethics Committee approved the study protocol 
(REC reference 10/H0405/2) and informed written consent was taken prior to 
subjects enrolling on to the study. Thirty individuals were recruited into three 
participant groups: asthma with fixed airflow obstruction (A+FAO), asthma 
without FAO (A-FAO), and healthy controls (H). All asthma subjects had a clinical 
diagnosis. Asthma patients with FAO had a post-bronchodilator FEV/FVC <0.7, 
despite clinician-optimised treatment [41]; while asthma patients without FAO 
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had a post-bronchodilator FEV/FVC ≥0.7. The bronchodilator (400μg 
salbutamol) was administered 20 minutes prior to spirometry. All participants 
were age-matched, had no co-morbidities, were ex or non-smokers with a pack 
history of ≤10years, and had no infections within the previous six weeks. The 
demographic and spirometric data of the 30 study participants used to 
investigate killer cell number, surface receptor expression and intracellular 
cytotoxic mediator expression are shown in Table 1a; details of the 20 
participants whose MAPK signalling molecule expression were analysed are 
shown in Table 1b; while the details of the 18 participants whose NK cell 
cytotoxicity levels were measured are shown in Table 1c. 
 
 
Absolute cell counting 
To quantify killer cell numbers, fluorescently labelled antibodies specific for 
several killer cell markers, shown in Table 2, were added to 100µl whole 
peripheral blood at half the recommended concentration and left in the dark for 
15 minutes. Optilyse C solution (Beckman Coulter, A11895) was used to lyse the 
red blood cells and was diluted with an equal volume of phosphate buffered 
saline (PBS, Sigma D8537) after 10 minutes. Finally, 100µl of flow-count 
fluorosphere beads (Beckman Coulter, 7547053) were added to each tube, 
before immediate analysis on a Beckman Coulter FC500 flow cytometer.  
 
Peripheral blood mononuclear cell (PBMC) and killer cell isolation 
To obtain PBMCs, peripheral whole blood was diluted to a ratio of 2:1 with 
RPMI-1640 media (Sigma, R8758), layered over histopaque (Sigma, H8889) and 
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centrifugated at 800g for 23 minutes. The resulting PBMC layer was harvested. 
CD8 T cells, NK cells and NKT-like cells were isolated from PBMCs via 
immunomagnetic separation using a CD56 multisort kit (Miltenyi Biotec, 130-
055-401) and CD3 and CD8 microbeads (Miltenyi Biotec, 130-050-101 and 130-
045-201, respectively) according to the supplied protocols. Briefly, PBMCs were 
incubated with CD56 microbeads, washed, and passed through an MS column 
situated within a MACS magnet. After microbead release, using the supplied 
reagent, and another wash, the CD56+ fraction was incubated with CD3 
microbeads; while the CD56- fraction was incubated with CD8 microbeads. Both 
fractions were run through a fresh MS column, which yielded a CD56+CD3- 
fraction (NK cells), a CD56+CD3+ fraction (NKT-like cells), and a CD56-CD8+ 
fraction (CD8 T cells). All reagents and incubation steps were used and 
performed at 4oC. A portion of each fraction was removed, stained extracellularly 
and analysed by flow cytometry to ascertain purity. The median CD8 T cell purity 
was above 92%, the median NK cell purity was above 97%, and the median NKT 
cell purity was above 74%.  
 
Flow cytometry 
Killer cell purity, surface receptor expression, and intracellular cytotoxic 
mediator expression were all analysed by flow cytometry. Briefly, cells were 
quick-fixed using a 3% formaldehyde fix solution. Those stained extracellularly 
were washed in phosphate buffered albumin (PBA- PBS (Oxoid BR0014G) with 
1% BSA (Sigma A7284) and 0.1% NaN3 (Sigma S8032)), incubated with 
fluorescently-conjugated antibodies (see Table 2) for 30 minutes in the dark, and 
washed again. Those stained intracellularly were washed with 0.04% PBA-
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saponin (Sigma, S4521) followed by PBA-saponin with 10% FCS, before a two-
hour incubation and a final wash in PBA-saponin. All cells were stored in a 0.5% 
formaldehyde fix solution until analysis. Fluorescence-minus-one controls, 
containing all the antibodies bar one, were also included. Flow cytometry 
analysis was performed on a Beckman Coulter FC500 flow cytometer, with 50 
000 events collected for each sample. Dead cells were excluded based on their 
forward (size) and side scatter (granularity). 
 
Reverse-phase protein microarray (RPPA) analysis 
An in-house cell lysate microarray system was used to quantify killer cell 
cytotoxic signalling molecule levels [42]. Briefly, samples were printed onto 16 
pad nitrocellulose slides (Grace BioLabs) using a Microgrid II arraying robot 
(Digilab Inc., Marlborough, MA, USA).  Slides were blocked, washed and probed 
with marker-specific rabbit antibodies (Cell Signaling Technology) and mouse 
anti-human β-actin control antibody (Sigma Aldrich, UK).  Antibody binding was 
visualized by incubating with goat anti-mouse IR680 and goat anti-rabbit IR00 
infrared secondary antibodies (Li-Cor BioSciences) diluted 1:5000 in 0.1% TBS-
Tween for 30 minutes in the dark.  Having been washed, rinsed with ultrapure 
water, and dried; the slides were scanned at 700nm and 800nm wavelengths on 
a Li-Cor Odyssey scanner (LI-COR Biosciences).   Fluorescent signal for each 
feature (spot) was determined using Axon GenePix Pro software (Axon 
Instruments Inc.)  Local background was subtracted and signals were 
normalized to β actin levels using the R statistical language and the RPPAnalyser 
module. 
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Cytotoxicity assay 
NK cell cytotoxicity was quantified using a non-radioactive LDH release assay kit 
(Promega, G1780) and the K562 human myelogenous leukaemia cell line 
(ECACC). The cell line was cultured in a 37oC incubator using RPMI-1640 media 
(Sigma, R8758) with 10% FCS (HyClone, CH30160.03). 
Kit instructions were followed. Briefly, the K562 and NK cells were 
washed twice in RPMI-1640 media without phenol red (Invitrogen, 11835063), 
and placed at an effector:target ratio of 10:1 in a U-bottomed 96 well tissue 
culture plate (Nunc, 163320), in quadruplicate. Following a four-hour incubation 
at 37oC and subsequent centrifugation, 50μl of supernatant from each well was 
transferred to a flat-bottomed 96 well tissue culture plate (Nunc, 167008) and 
mixed with an equal volume of substrate mix (supplied with kit) to quantify LDH 
levels. After 30 minutes in the dark, th  reaction was stopped and the 
absorbance read at 492nm on a BMG Labtech FLUOstar Optima 
spectrophotometer. Cytotoxicity was calculated as a percentage using the 
following equation: 
Cytotoxicity (%)= [(effector/target mix− spontaneous effector LDH 
release− spontaneous target LDH release)/(maximum target LDH release− 
spontaneous target LDH release)] x 100  
  
Statistical analysis 
Flow cytometry data were analysed using Weasel v2.7 software. The spot 
intensity of the microarray samples was measured using Genepix software, 
before RPPanalyzer software corrected for background, normalised to the actin 
signal of the same spot, and amplified the intensity of each spot. Subsequent 
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analysis of all data was performed with Prism 4.0 software. For visibly skewed 
data, the values were first log transformed, before the normality of the data was 
tested using the D’Agostino and Pearson omnibus normality test. Differences 
between parametric data were explored using the one-way ANOVA test, while 
differences between non-parametric data were explored using the Kruskal 
Wallis test. Any pairs of groups holding statistical significance (p<0.05) following 
the ANOVA test were identified using the Tukey’s multiple comparison post-hoc 
test.   
 
Results 
 
Peripheral killer cell numbers 
Peripheral CD8 T cell (CD8+CD3+CD56-), NK cell (CD56+CD3-) and NKT-like cell 
(CD56+CD3+) numbers were quantified using absolute cell counting (Fig. 1). 
There were no statistically significant differences between the numbers or 
proportions of each killer cell type across the three participant groups (asthma 
patients with or without FAO and healthy controls).  
Subsets of the killer cell types were also quantified using this method 
(data not shown). These subsets included: naïve (CD45RA+CCR7+), central 
memory (CM, CD45RA-CCR7+), effector memory (EM, CD45RA-CCR7-) and 
effector T (Eff T, CD45RA+CCR7-) CD8 T cells [43]; CD56dim (CD56+/CD16+) and 
CD56bright (CD56++/CD16-) NK cells [44]; and CD4-CD8-, CD4+CD8-, CD4-CD8+ and 
CD4+CD8+ NKT-like cells [45]. Again, no significant differences were seen 
between the three participant groups for any of these subsets.  
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Peripheral killer cell NKG2D and KIR3DL1 receptor expression 
Peripheral killer cell ex vivo expression of the activatory NKG2D and inhibitory 
KIR3DL1 receptors was quantified using flow cytometry (Fig. 2). No statistically 
significant differences were present between the participant groups for NKG2D 
or KIR3DL1 expression for any of the killer cell types.  
The killer cell expression of a further four receptors (activatory KLRC2 
and KIR2DS4, and inhibitory KLRD1 and KIR2DL2) was analysed by RPMA (data 
not shown). There were no significant differences in the expression of these four 
receptors between the participant groups for any of the killer cell types.  
 
Peripheral killer cell cytotoxic signalling molecule expression 
Peripheral CD8 T cells, NK cells and NKT-like cells were isolated (to purities of 
>92%, >97% and >74%, respectively), before their expression of total and 
phosphorylated ERK1/2, total and phosphorylated SAPK/JNK and total p38 
MAPK was measured by RPMA and compared between asthma patients with and 
without FAO and healthy individuals (Fig. 3). There were no significant 
differences in the expression of the aforementioned signalling molecules in the 
three isolated killer cell types.  
 
Peripheral killer cell cytotoxic function 
The peripheral killer cell ex vivo intracellular expression of the cytotoxic 
mediators perforin and granzyme B was analysed by flow cytometry and 
compared across the three participant groups (Fig. 4). There were no significant 
differences in the expression of either of these cytotoxic mediators between the 
participant groups for any of the three killer cell types. While most CD8 T cells 
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expressed neither perforin nor granzyme B (Fig. 4a); the majority of NK cells 
expressed both cytotoxic mediators (Fig. 4f).  
Peripheral NK cells were isolated to a purity of over 97%, before their 
cytotoxicity levels were quantified using the K562 cell line and a non-radioactive 
LDH release assay (Fig. 5). There were no statistically significant differences in 
NK cell cytotoxicity levels between the three participant groups. 
 
Discussion 
 
The work presented here shows that the number and function of killer cells in a 
small subset of asthma patients who display FAO are similar to those in asthma 
patients without FAO and in healthy controls.  This is distinctly different from 
our previous findings concerning peripheral killer cells in COPD [40, 46].  
CD8 T cell subsets can have opposing effects in asthma: Tc1 CD8 T cells 
protect against asthma, by mediating IL-12 and IL-18 Th1 cytokine production 
from dendritic cells [26]; whereas Tc2 CD8 T cells are thought to contribute to 
the inflammatory profile seen in asthma patients [26]. NK cell subsets have also 
been shown to have opposing effects in asthma [27, 31, 35].  NKT cells have been 
implicated in asthma [25, 30] as they produce Th2 cytokines, such as IL-4, IL-5 
and IL-13, which recruit eosinophils and promote B cell class switching [32-34]. 
However, NKT cells are also capable of cytotoxicity and producing Th1 cytokines; 
thereby inhibiting the actions of the Th2 cytokine-producing NKT cells involved 
in the pathogenesis of asthma [28, 29, 36].  
No significant differences were observed in peripheral NK or NKT-like cell 
numbers or proportions between the three participant groups in the present 
study (healthy controls, asthma patients without FAO and asthma patients with 
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FAO), whereas COPD patients were found to have significantly lower proportions 
of peripheral NK and NK-T cells than healthy controls (both never-smokers and 
smokers) [40].  A point of caution in drawing firm conclusions from the present 
results is the relatively small numbers of subjects in the healthy control, asthma 
without FAO and asthma with FAO groups, which limits the power of the study; 
although, having said that, similar numbers of subjects were used in our previous 
study that did show significant differences between peripheral killer cells in 
COPD patients and healthy controls [40].  However, it is clear that any 
differences in the number or proportions of killer cells between the healthy 
control, asthma without FAO and asthma with FAO groups are marginal, since 
power calculations showed that the numbers of subjects in each group required 
for 80% power would need to be 121 for the proportion of CD8 T cells, 468 for 
NK cell proportions and 84 for NKT-like cell proportions.  Furthermore, 
modelling of the data in figure 1 with ten times more data points (but with the 
same distribution of data) still did not predict there to be any significant 
differences in killer cell numbers/proportions between the asthma patients 
without or with FAO. 
In addition, no significant differences were observed in the proportion of 
peripheral CD8 T cells or NKT-like cells expressing both perforin and granzyme 
B between the three participant groups in the present study, whereas these 
proportions were found to be significantly decreased in COPD patients compared 
to healthy controls (both never-smokers and smokers) [40].  Again, despite the 
relatively small size of the healthy control, asthma without FAO and asthma with 
FAO groups in the present study, the lack of significant differences in the 
proportions of perforin+/granzyme-B+ cells is supported by power calculations 
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indicating that the number of subjects required for 80% power would be 2113 
for CD8+ T cells, 201 for NK cells and 1875 for NKT-like cells; and that modelling 
of the data with ten time more data points and the same distributions still 
predicts there to be no significant differences. 
Furthermore, no significant differences were observed in the cytotoxic 
activity of peripheral NK cells between the three participant groups in the 
present study, whereas these cells were found to have significantly lower 
cytotoxic activity in COPD patients than in healthy controls (both never-smokers 
and smokers) [40].  However, the relatively small group sizes require there to be 
cautious interpretation of the data. 
Overall, with respect to these observations concerning peripheral killer 
cells, asthma with FAO is unlike COPD and is more akin to asthma without FAO.  
This is despite FAO being a feature more usually associated with COPD than with 
asthma.  In otherwords, asthma with FAO displays a combination of features that 
distinguish it both from asthma without FAO and from COPD. 
 Expression of KIR3DL1 (also known as CD158e1) by peripheral killer 
cells does not distinguish asthma with or without FAO from COPD, since this is 
unchanged in all three of these disease states compared to healthy (never-
smoker) controls [46]; indeed, smoking per se (rather than COPD) leads to 
reduced KIR3DL1/CD158e1 expression by peripheral killer cells [46].  NKG2D 
expression by peripheral killer cells is also normal in asthma with or without 
FAO and in COPD [46]. 
With regards to the signalling molecule expression results, no significant 
differences were observed between healthy controls and asthma patients with or 
without FAO. It is, however, interesting to note the similarities between the NK 
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cell profiles of phosphorylated (activated) ERK1/2 and cellular cytotoxicity. In 
both, the levels in healthy individuals and asthma patients with FAO were 
similar, while those of asthma patients without FAO were slightly elevated 
(although not significantly – possibly due to insufficient numbers). ERK1/2 is 
necessary for NK cell cytotoxicity [47, 48] and has been shown to be elevated in 
asthma patients without FAO compared to healthy individuals [49]. This is the 
first time it has been specifically investigated in asthma patients with FAO. 
A key difference in the pathology of COPD compared to asthma with FAO 
is the association of chronic bronchitis and/or emphysema with COPD.  Our 
findings in relation to killer cells in COPD and, reported here, for asthma with or 
without FAO, may help to explain these differences.  In particular, the reduced 
numbers and effector function of peripheral killer cells in COPD [40] was found 
to correlate inversely with increased numbers, activation state and effector 
function of lung-associated killer cells in the induced sputum of COPD patients 
[37, 46].  Thus, the recruitment to pulmonary tissues, and activation, of killer 
cells in COPD may contribute to the inflammation and tissue destruction leading 
to the development of chronic bronchitis and/or emphysema.  Conversely, the 
relatively normal numbers and function of peripheral killer cells in asthma with 
or without FAO may be indicative of their lack of recruitment to the lungs and 
the absence of chronic bronchitis and emphysema.   It is thus apparent that a 
main limitation of the present study is that only peripheral killer cells were 
investigated. Although inflammatory cells are recruited from the periphery to 
the lung, both the origin of systemic inflammation and its relationship to the 
pulmonary inflammation of asthma remain unclear [50]. Therefore, although 
these results are clinically relevant, further study using material derived from 
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the lung would be required to show the recruitment, and the potential role, of 
killer cells in the pathogenesis of asthma with FAO.  
Although the present study does not elucidate the basis for the different 
features of asthma without or with FAO, it does imply that this is not a 
consequence of differences in killer cell numbers or activity.  Further studies are 
therefore required to understand these differences. 
Regarding our definition of FAO (post-bronchodilator FEV/FVC <0.7, 
despite clinician-optimised treatment [41]), we believe the length of disease 
duration of the asthma patients with FAO (a median of 45 years) allowed us to 
classify this airflow obstruction as fixed; although repeated spirometry 
measurements would have been desirable.  Furthermore, an oral corticosteroid 
trial could be considered necessary to fully confirm fixed airflow obstruction but, 
as all patients were on inhaled steroids, this was not deemed ethically 
acceptable. 
In summary, the three main types of killer cells – CD8 T cells, NK cells and 
NKT-like cells – are similar in peripheral blood in asthma patients and healthy 
controls.  The observation that peripheral killer cells are similar in asthma with 
FAO and in asthma without FAO indicates that peripheral killer cell phenotype 
and function is not linked to the differences in lung function associated with 
these clinically distinct endotypes of asthma. Furthermore, these findings are 
different from our previous observations concerning peripheral killer cells in 
COPD [40], indicating that asthma with FAO and COPD are distinct phenotypes. 
 
 
 
Page 14 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 15
References 
1. Ferkol T, Schraufnagel D: The global burden of respiratory disease. Ann 
Am Thorac Soc 2014, 11:404-406. 
2. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D, 
Group EC: Allergic vs nonallergic asthma: what makes the difference? 
Allergy 2002, 57:607-613. 
3. Agache I, Akdis C, Jutel M, Virchow JC: Untangling asthma phenotypes and 
endotypes. Allergy 2012, 67:835-846. 
4. Corren J: Asthma phenotypes and endotypes: an evolving paradigm for 
classification. Discov Med 2013, 15:243-249. 
5. George BJ, Reif DM, Gallagher JE, Williams-DeVane CR, Heidenfelder BL, 
Hudgens EE, Jones W, Neas L, Hubal EA, Edwards SW: Data-driven asthma 
endotypes defined from blood biomarker and gene expression data. PLoS 
One 2015, 10:e0117445. 
6. Bell MC, Busse WW: Is It Asthma or Is It COPD: The Overlap Syndrome. J 
Allergy Clin Immunol Pract 2015, 3:641-642; quiz 643. 
7. Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, 
Takekoshi D, Kikuchi T, Ohta K, Ichinose M: Biomarker-based detection of 
asthma-COPD overlap syndrome in COPD populations. Int J Chron 
Obstruct Pulmon Dis 2015, 10:2169-2176. 
8. Vanfleteren LE, Kocks JW, Stone IS, Breyer-Kohansal R, Greulich T, 
Lacedonia D, Buhl R, Fabbri LM, Pavord ID, Barnes N, et al: Moving from 
the Oslerian paradigm to the post-genomic era: are asthma and COPD 
outdated terms? Thorax 2014, 69:72-79. 
9. Boulet LP, Turcotte H, Turcot O, Chakir J: Airway inflammation in asthma 
with incomplete reversibility of airflow obstruction. Respir Med 2003, 
97:739-744. 
10. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, Chung 
KF: Parameters associated with persistent airflow obstruction in chronic 
severe asthma. Eur Respir J 2004, 24:122-128. 
11. Di Lorenzo G, Mansueto P, Ditta V, Esposito-Pellitteri M, Lo Bianco C, Leto-
Barone MS, D'Alcamo A, Farina C, Di Fede G, Gervasi F, et al: Similarity and 
differences in elderly patients with fixed airflow obstruction by asthma 
and by chronic obstructive pulmonary disease. Respir Med 2008, 
102:232-238. 
12. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, 
Ligabue G, Ciaccia A, Saetta M, Papi A: Differences in airway inflammation 
in patients with fixed airflow obstruction due to asthma or chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:418-
424. 
13. Guerra S, Martinez FD: Epidemiology of the origins of airflow limitation in 
asthma. Proc Am Thorac Soc 2009, 6:707-711. 
14. Guerra S, Sherrill DL, Kurzius-Spencer M, Venker C, Halonen M, Quan SF, 
Martinez FD: The course of persistent airflow limitation in subjects with 
and without asthma. Respir Med 2008, 102:1473-1482. 
15. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE: Risk 
factors associated with persistent airflow limitation in severe or difficult-
Page 15 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 16
to-treat asthma: insights from the TENOR study. Chest 2007, 132:1882-
1889. 
16. Selivanova PA, Kulikov ES, Kozina OV, Gereng EA, Freidin MB, Ogorodova 
LM: Morphological and molecular characteristics of "difficult" asthma. J 
Asthma 2010, 47:269-275. 
17. Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, 
Brightling CE, Wardlaw AJ, Pavord ID: Association between neutrophilic 
airway inflammation and airflow limitation in adults with asthma. Chest 
2007, 132:1871-1875. 
18. Tsoumakidou M, Tzanakis N, Kyriakou D, Chrysofakis G, Siafakas NM: 
Inflammatory cell profiles and T-lymphocyte subsets in chronic 
obstructive pulmonary disease and severe persistent asthma. Clin Exp 
Allergy 2004, 34:234-240. 
19. van Rensen EL, Sont JK, Evertse CE, Willems LN, Mauad T, Hiemstra PS, 
Sterk PJ: Bronchial CD8 cell infiltrate and lung function decline in asthma. 
Am J Respir Crit Care Med 2005, 172:837-841. 
20. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS: 
Risk factors associated with the presence of irreversible airflow limitation 
and reduced transfer coefficient in patients with asthma after 26 years of 
follow up. Thorax 2003, 58:322-327. 
21. Fattahi F, Vonk JM, Bulkmans N, Fleischeuer R, Gouw A, Grunberg K, 
Mauad T, Popper H, Felipe-Silva A, Vrugt B, et al: Old dilemma: asthma 
with irreversible airway obstruction or COPD. Virchows Arch 2015, 
467:583-593. 
22. Zhang L, He L, Gong J, Liu C: Risk Factors Associated with Irreversible 
Airway Obstruction in Asthma: A Systematic Review and Meta-Analysis. 
Biomed Res Int 2016, 2016:9868704. 
23. Tubby C, Harrison T, Todd I, Fairclough L: Immunological basis of 
reversible and fixed airways disease. Clinical science 2011, 121:285-296. 
24. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients 
with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 
23:932-946. 
25. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, 
DeKruyff RH, Umetsu DT: CD4+ invariant T-cell-receptor+ natural killer T 
cells in bronchial asthma. N Engl J Med 2006, 354:1117-1129. 
26. Betts RJ, Kemeny DM: CD8+ T cells in asthma: friend or foe? Pharmacol 
Ther 2009, 121:123-131. 
27. Culley FJ: Natural killer cells in infection and inflammation of the lung. 
Immunology 2009, 128:151-163. 
28. Godfrey DI, Kronenberg M: Going both ways: immune regulation via 
CD1d-dependent NKT cells. J Clin Invest 2004, 114:1379-1388. 
29. Kuylenstierna C, Bjorkstrom NK, Andersson SK, Sahlstrom P, Bosnjak L, 
Paquin-Proulx D, Malmberg KJ, Ljunggren HG, Moll M, Sandberg JK: 
NKG2D performs two functions in invariant NKT cells: direct TCR-
independent activation of NK-like cytolysis and co-stimulation of 
activation by CD1d. Eur J Immunol 2011, 41:1913-1923. 
30. Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, 
Shiratsuchi T, Hnatiuk NE, Howell AR, et al: A CD1d-dependent antagonist 
inhibits the activation of invariant NKT cells and prevents development of 
Page 16 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 17
allergen-induced airway hyperreactivity. J Immunol 2010, 184:2107-
2115. 
31. Ple C, Barrier M, Amniai L, Marquillies P, Bertout J, Tsicopoulos A, Walzer 
T, Lassalle P, Duez C: Natural killer cells accumulate in lung-draining 
lymph nodes and regulate airway eosinophilia in a murine model of 
asthma. Scandinavian Journal of Immunology 2010, 72:118-127. 
32. Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T: Invariant 
NKT cells biased for IL-5 production act as crucial regulators of 
inflammation. J Immunol 2007, 179:3452-3462. 
33. Stock P, Lombardi V, Kohlrautz V, Akbari O: Induction of airway 
hyperreactivity by IL-25 is dependent on a subset of invariant NKT cells 
expressing IL-17RB. J Immunol 2009, 182:5116-5122. 
34. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, Hase K, Iwamura 
C, Nakajima H, Nakayama T, Taniguchi M: A novel subset of mouse NKT 
cells bearing the IL-17 receptor B responds to IL-25 and contributes to 
airway hyperreactivity. J Exp Med 2008, 205:2727-2733. 
35. Wei H, Zhang J, Xiao W, Feng J, Sun R, Tian Z: Involvement of human 
natural killer cells in asthma pathogenesis: natural killer 2 cells in type 2 
cytokine predominance. J Allergy Clin Immunol 2005, 115:841-847. 
36. Wingender G, Krebs P, Beutler B, Kronenberg M: Antigen-specific 
cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and 
is correlated with antigenic potency. J Immunol 2010, 185:2721-2729. 
37. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC: Enhanced 
effector function of cytotoxic cells in the induced sputum of COPD 
patients. Respir Res 2010, 11:76-84. 
38. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, 
Byers DE, Alevy Y, Tucker J, et al: Persistent activation of an innate 
immune response translates respiratory viral infection into chronic lung 
disease. Nat Med 2008, 14:633-640. 
39. Fairclough L, Urbanowicz RA, Corne J, Lamb JR: Killer cells in chronic 
obstructive pulmonary disease. Clin Sci (Lond) 2008, 114:533-541. 
40. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC: Altered effector 
function of peripheral cytotoxic cells in COPD. Respir Res 2009, 10:53-65. 
41. GOLD: Global strategy for the diagnosis, management and prevention of 
chronic obstructive pulmonary disease. . 2013. 
42. Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, 
Fairclough LC, Tighe PJ: A pro-inflammatory signalome is constitutively 
activated by C33Y mutant TNF receptor 1 in TNF receptor-associated 
periodic syndrome (TRAPS). Eur J Immunol 2014, 44:2096-2110. 
43. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay 
V, Rizzardi GP, Fleury S, Lipp M, et al: Skewed maturation of memory HIV-
specific CD8 T lymphocytes. Nature 2001, 410:106-111. 
44. Lanier LL, Testi R, Bindl J, Phillips JH: Identity of Leu-19 (CD56) leukocyte 
differentiation antigen and neural cell adhesion molecule. J Exp Med 
1989, 169:2233-2238. 
45. Godfrey DI, Stankovic S, Baxter AG: Raising the NKT cell family. Nat 
Immunol 2010, 11:197-206. 
46. Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC: 
Differential activation of killer cells in the circulation and the lung: a study 
Page 17 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 18
of current smoking status and chronic obstructive pulmonary disease 
(COPD). PLoS One 2013, 8:e58556. 
47. Li C, Ge B, Nicotra M, Stern JN, Kopcow HD, Chen X, Strominger JL: JNK 
MAP kinase activation is required for MTOC and granule polarization in 
NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci U S A 2008, 
105:3017-3022. 
48. Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL: Many NK cell 
receptors activate ERK2 and JNK1 to trigger microtubule organizing 
center and granule polarization and cytotoxicity. Proc Natl Acad Sci U S A 
2007, 104:6329-6334. 
49. Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R: Cell-specific 
activation profile of extracellular signal-regulated kinase 1/2, Jun N-
terminal kinase, and p38 mitogen-activated protein kinases in asthmatic 
airways. J Allergy Clin Immunol 2008, 121:893-902 e892. 
50. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH: Systemic and local 
inflammation in asthma and chronic obstructive pulmonary disease: is 
there a connection? Proc Am Thorac Soc 2009, 6:638-647. 
51. GINA: Global strategy for asthma management and prevention. 2012; 
http://www.ginasthma.org/documents/5/documents_variants/37. 
 
  
Page 18 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 19
Figure legends 
Figure 1. Peripheral killer cell numbers in asthma patients with and without 
FAO (A+FAO, A-FAO) and healthy individuals (H). Whole blood was mixed with 
flow-count fluorosphere beads, incubated with fluorescently-conjugated 
antibodies and analysed by flow cytometry. Lymphocytes (L) and flow-count 
fluorosphere beads (B) were identified based on forward and side scatter (a). 
CD8 T cells (CD8+CD3+CD56-, b-e), NK cells (CD56+CD3-, f-i) and NKT-like cells 
(CD56+CD3+, j-l) were identified from the lymphocyte population 
(representative plots shown) and displayed as cells per μl (d, h, k) and as a 
proportion of the total killer cell number (e, i, l). There were no statistically 
significant differences in killer cell number, or the proportion of the killer cell 
total this value represented, between the three participant groups for any of the 
three killer cell types. (h) and (k) log transformed. All data analysed by ANOVA. 
 
Figure 2. NKG2D and KIR3DL1 receptor expression in killer cells from asthma 
patients with and without FAO (A+FAO, A-FAO) and healthy individuals (H). 
Separated PBMC were stained with fluorescently-conjugated antibodies and 
analysed by flow cytometry. CD8 T cells (a-c), NK cells (d-f) and NKT-like cells 
(g-i) were identified (representative plots shown), and the NKG2D and KIR3DL1 
expression of each was displayed as mean fluorescence intensity (MFI). There 
were no statistically significant differences in NKG2D or KIR3DL1 expression 
between the three participant groups for any of the killer cell types. (i) Log 
transformed. All data analysed by ANOVA. 
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Figure 3. MAPK signalling molecule expression in killer cells from asthma 
patients with and without FAO (A+FAO, A-FAO) and healthy individuals (H). 
Levels of total (T) and phosphorylated (P) ERK1/2, SAPK/JNK and p38 MAPK 
were measured in isolated CD8 T cells (a-e), NK cells (f-j) and NKT-like cells (k-
o), by reverse phase protein lysate microarray (RPMA). Background values were 
subtracted from the signal intensities, before normalisation to actin expression. 
There were no statistically significant differences in the expression of any of the 
signalling molecules between the three participant groups for any of the three 
killer cell types. Values are expressed in relative fluorescent units (RFU). (b), (e), 
(k), (l) and (o) Log transformed. All data analysed by ANOVA, except (j)- 
analysed by Kruskal Wallis. 
 
Figure 4. Perforin and granzyme B expression in killer cells from asthma 
patients with and without FAO (A+FAO, A-FAO) and healthy individuals (H). 
PBMC were isolated and stained with fluorescently-conjugated antibodies before 
analysis by flow cytometry. CD8 T cells (a-d), NK cells (e-h) and NKT-like cells (i-
l) were identified and the perforin and/or granzyme B expression of each was 
quantified. There were no statistically significant differences in the expression of 
either of the two cytotoxic mediators between the three participant groups for 
any of the killer cell types. (c), (d), (h), (k) and (l) Log transformed. All data 
analysed by ANOVA, except (j)- analysed by Kruskal Wallis. 
  
Figure 5. NK cell cytotoxicity in asthma patients with and without FAO (A+FAO, 
A-FAO) and healthy individuals (H). Isolated peripheral NK cells were incubated 
with target K562 cells for 4 hours, and lactate dehydrogenase (LDH) levels used 
Page 20 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 21
to determine cytotoxicity levels. There were no statistically significant 
differences in NK cell cytotoxicity levels between the three participant groups. 
Data analysed by ANOVA.  
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Figure 1. Peripheral killer cell numbers in asthma patients with and without FAO (A+FAO, A-FAO) and 
healthy individuals (H). Whole blood was mixed with flow-count fluorosphere beads, incubated with 
fluorescently-conjugated antibodies and analysed by flow cytometry. Lymphocytes (L) and flow-count 
fluorosphere beads (B) were identified based on forward and side scatter (a). CD8 T cells (CD8+CD3+CD56-
, b-e), NK cells (CD56+CD3-, f-i) and NKT-like cells (CD56+CD3+, j-l) were identified from the lymphocyte 
population (representative plots shown) and displayed as cells per µl (d, h, k) and as a proportion of the 
total killer cell number (e, i, l). There were no statistically significant differences in killer cell number, or the 
proportion of the killer cell total this value represented, between the three participant groups for any of the 
three killer cell types. (h) and (k) log transformed. All data analysed by ANOVA.  
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Figure 2. NKG2D and KIR3DL1 receptor expression in killer cells from asthma patients with and without FAO 
(A+FAO, A-FAO) and healthy individuals (H). Separated PBMC were stained with fluorescently-conjugated 
antibodies and analysed by flow cytometry. CD8 T cells (a-c), NK cells (d-f) and NKT-like cells (g-i) were 
identified (representative plots shown), and the NKG2D and KIR3DL1 expression of each was displayed as 
mean fluorescence intensity (MFI). There were no statistically significant differences in NKG2D or KIR3DL1 
expression between the three participant groups for any of the killer cell types. (i) Log transformed. All data 
analysed by ANOVA.  
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Figure 3. MAPK signalling molecule expression in killer cells from asthma patients with and without FAO 
(A+FAO, A-FAO) and healthy individuals (H). Levels of total (T) and phosphorylated (P) ERK1/2, SAPK/JNK 
and p38 MAPK were measured in isolated CD8 T cells (a-e), NK cells (f-j) and NKT-like cells (k-o), by 
reverse phase protein lysate microarray (RPMA). Background values were subtracted from the signal 
intensities, before normalisation to actin expression. There were no statistically significant differences in the 
expression of any of the signalling molecules between the three participant groups for any of the three killer 
cell types. Values are expressed in relative fluorescent units (RFU). (b), (e), (k), (l) and (o) Log 
transformed. All data analysed by ANOVA, except (j)- analysed by Kruskal Wallis.  
 
253x576mm (72 x 72 DPI)  
 
 
Page 24 of 29
URL: http://mc.manuscriptcentral.com/ljas
Journal of Asthma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Figure 4. Perforin and granzyme B expression in killer cells from asthma patients with and without FAO 
(A+FAO, A-FAO) and healthy individuals (H). PBMC were isolated and stained with fluorescently-conjugated 
antibodies before analysis by flow cytometry. CD8 T cells (a-d), NK cells (e-h) and NKT-like cells (i-l) were 
identified and the perforin and/or granzyme B expression of each was quantified. There were no statistically 
significant differences in the expression of either of the two cytotoxic mediators between the three 
participant groups for any of the killer cell types. (c), (d), (h), (k) and (l) Log transformed. All data analysed 
by ANOVA, except (j)- analysed by Kruskal Wallis.  
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Figure 5. NK cell cytotoxicity in asthma patients with and without FAO (A+FAO, A-FAO) and healthy 
individuals (H). Isolated peripheral NK cells were incubated with target K562 cells for 4 hours, and lactate 
dehydrogenase (LDH) levels used to determine cytotoxicity levels. There were no statistically significant 
differences in NK cell cytotoxicity levels between the three participant groups. Data analysed by ANOVA.  
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Table 1. Subject demographic and spirometric data 
           (a) Full cohort- cell numbers, receptor 
expression and cytotoxic mediator expression 
(b) MAPK signalling pathways (c) NK cell cytotoxicity 
 H A-FAO A+FAO H A-FAO A+FAO H A-FAO A+FAO 
Subjects 9 7 14 7 3 10 4 5 9 
Age (years) 57 (52-62) 66 (60-74) 67 (58-71) 55 (49-57) 64 (60-74) 68 (58-73) 56 (51-59) 73 (58-75) 65 (56-68) 
Gender (M/F) 6/3 1/6 9/5 5/2 0/3 8/2 2/2 0/5 7/2 
Post-bronch FEV1 (L) 
3.14 (2.92-
3.96) 
2.05 (1.62-
2.78) 
1.73 (1.47-
2.10) 
3.14 (3.02-
4.14) 
2.02 (1.62-
2.18) 
1.65 (1.55-
1.80) 
2.98 (2.81-
3.89) 
2.05 (1.58-
2.52) 
1.69 (1.43-
1.80) 
Post-bronch FEV1 
(%pred) 
112 (101-
117) 
103 (97-110) 64 (55-76) 109 (95-113) 98 (97-116) 64 (55-79) 114 (108-121) 103 (95-113) 59 (46-70) 
Post-bronch FVC (L) 
4.05 (3.71-
4.78) 
2.73 (2.22-
3.75) 
2.89 (2.39-
4.02) 
4.05 (3.68-
4.98) 
2.73 (2.22-
2.89) 
3.07 (2.50-
4.02) 
3.82 (3.46-
4.79) 
2.40 (2.07-
3.24) 
3.08 (2.36-
4.17) 
Post-bronch FVC (%pred) 
110 (102-
121) 
116 (100-121) 88 (76-109) 106 (100-118) 116 (110-121) 84 (76-105) 115 (108-132) 110 (97-122) 90 (76-101) 
Post-bronch FEV1/FVC 
0.81 (0.78-
0.83) 
0.76 (0.73-
0.80) 
0.59 (0.50-
0.67) 
0.82 (0.79-
0.83) 
0.73 (0.70-
0.80) 
0.59 (0.51-
0.67) 
0.78 (0.76-
0.82) 
0.80 (0.75-
0.83) 
0.55 (0.46-
0.59) 
Airflow obstruction 
severity (mild/moderate/ 
severe/ very severe)* 
n/a n/a 3/8/2/1 n/a n/a 2/6/2/0 n/a n/a 1/5/2/1 
Age of asthma onset 
(years) 
n/a 46 (39-54) 8 (6-51) n/a 50 (42-53) 8 (6-42) n/a 50 (41-55) 10 (6-56) 
Disease duration (years) n/a 22 (15-30) 45 (18-59) n/a 24 (6-30) 53 (20-63) n/a 20 (12-27) 47 (11-57) 
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Asthma severity (GINA 
treatment step 
1/2/3/4/5)** 
n/a 0/3/3/1/0 0/1/7/6/0 n/a 0/1/1/1/0 0/1/4/4/0 n/a 0/2/2/1/0 0/1/3/5/0 
Inhaled corticosteroids 
(ICS) (Y/N) 
n/a 7/0 14/0 n/a 3/0 10/0 n/a 5/0 9/0 
Long-acting beta agonists 
(LABAs) (Y/N) 
n/a 2/5 9/5 n/a 0/3 6/4 n/a 2/3 7/2 
Short-acting beta agonists 
(SABAs) (Y/N) 
n/a 7/0 12/2 n/a 3/0 10/0 n/a 5/0 7/2 
Leukotriene modifiers 
(Y/N) 
n/a 0/7 1/13 n/a 0/3 1/2 n/a 0/5 1/8 
Atopic (Y/N) 2/7 6/1 9/5 1/6 3/0 7/3 0/4 5/0 6/3 
Smoking status 
(current/ex/never) 
0/1/8 0/4/3 0/2/12 0/1/6 0/2/1 0/1/9 0/0/4 0/2/3 0/0/9 
Pack years 0 (0-0) 1 (0-2) 0 (0-0) 0 (0-1.5) 1.5 (0-2) 0 (0-0) 0 (0-0) 0 (0-1.5) 0 (0-0) 
CD8 T cell purity (%)    93.6 (90.9-
95.0) 
92.9 (83.9-95) 
91.9 (88.4-
94.2) 
   
NK cell purity (%) 
   
97.5 (95.7-
98.3) 
97.3 (96.5-
98.1) 
97 (93.6-98.8) 
97.9 (96.2-
98.4) 
97.6 (96.3-
98.1) 
97.6 (93.3-
98.3) 
NKT-like cell purity (%)    82.5 (71.2-
90.0) 
75.7 (55.4-
92.4) 
73.9 (58.1-
92.6) 
   
Results expressed as the median with the interquartile range in brackets. A+/-FAO, asthma patients with/without fixed airflow obstruction; H, healthy individuals. 
*Based on post-bronchodilator FEV1 (%pred): >80% mild, 50-79% moderate, 30-49% severe, and <30% very severe. **Based on drug treatment [51]. 
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Table 2. Antibodies used in flow cytometry and reverse phase protein lysate 
microarray (RPMA) 
Target Conjugate Clone Company 
Catalogue 
number 
Lot number 
          Flow cytometry 
CD3 ECD UCHT1 Beckman Coulter A07748 30 
CD3 PC7 UCHT1 Beckman Coulter 737657 7973014 
CD8 ECD SFCI21Thy2D3 Beckman Coulter 737659 7974018 
CD8 PC5 HIT8a BD Pharmingen 555636 98195 
CD56 PE N901 (NHK-1) Beckman Coulter A07788 13 
CD56 PC5 N901 (NHK-1) Beckman Coulter A07789 15 
Granzyme B FITC GB11 BD Pharmingen 560211 37817 
KIR3DL1 FITC DX9 BioLegend 312706 B110125 
NKG2D PE ON72 Beckman Coulter A08934 13 
Perforin PE δG9 BD Pharmingen 556437 46510 
          Reverse phase protein lysate microarray (RPMA) 
T ERK1/2 - - Cell Signalling 4695 13 
T p38MAPK - - Cell Signalling 9212 13 
T SAPK/JNK - - Cell Signalling 9258 9 
P ERK1/2 - - Cell Signalling 9101 26 
P SAPK/JNK - - Cell Signalling 4668 7 
CD, cluster of differentiation; ECD, phycoerythrin-Texas Red; ERK1/2, extracellular signal-
regulated kinase 1 and 2; FITC, fluorescein isothiocyanate; PC5, phycoerythrin cyanin 5; KIRx, 
killer cell immunoglobulin-like receptor x; KLRx, killer cell lectin-like receptor x; P, 
phosphorylated; p38 MAPK, p38 mitogen-activated protein kinase; PC7, phycoerythrin cyanin 7; 
PE, phycoerythrin. SAPK/JNK, stress-activated protein kinase and c-Jun N-terminal kinase; T, 
total. 
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